PREVENT is a multicentre, 2x2 factorial, randomized clinical trial that aims to determine the
effect of cytisine versus placebo, as well as the effect of text messaging to support smoking
cessation versus standard of care in perioperative patients. This trial aims to investigate
the effects of cytisine and text messaging on 6-month continuous abstinence rates. PREVENT
will also assess secondary outcomes at 30 days, 56 days and 6 months post-randomization:
7-day point prevalence abstinence, urge to smoke, time to first lapse, time to relapse,
number of cigarettes smoking if still smoking, pulmonary complications, vascular
complications, wound and infectious complications, stroke, time in hospital and acute
hospital care.